$50m In New Capital Could Help Moximed Spring Into US Earlier

 
• By Tina Tan

In its latest and biggest fundraising to date, Moximed has bagged $50m in a series C round, which will help the company take its joint-unloading technology for osteoarthritis patients through US approval and into early commercialization.

Moximed Inc. is now well funded to see its US regulatory plans through for joint-unloading devices after raising $50m in a series C financing round. The money should also help the firm begin commercialization in what CEO Kevin Sidow believes will be a very receptive market for Moximed's osteoarthritis-relieving technology.

The series C round brought in new investors, Advent Life Sciences and Future Fund, and included participation by existing investors:...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area